--- title: "TRIUMPH-3: Retatrutide Phase 3 Results | Primara Labs" url: https://www.primaralabs.com/research/trials/triumph-3 source: Primara Labs, markdown mirror of the HTML page --- # TRIUMPH-3 In TRIUMPH-3, a phase 3 trial of retatrutide in adults with severe obesity (BMI of 35 or more) and established cardiovascular disease, with or without type 2 diabetes (n=1,949), mean body weight fell 21.6% on 9 mg and 22.6% on 12 mg over 80 weeks, against 3.2% on placebo (efficacy estimand; Eli Lilly topline release, 23 July 2026). Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked. Updated 24 September 2026 Retatrutide Explained: Triple Agonist Research (Philippines Guide)1:50·[Transcript and chapters](https://www.primaralabs.com/videos/retatrutide) ## Results Mean percent change in body weight by arm, as each source reports it. Navy bars are the trial arms, grey bars the comparator. Bars from different trials are not a head-to-head comparison: populations, durations and estimands differ. In a pre-specified in-study analysis of time to first MACE-5 event, pooled retatrutide against placebo had a hazard ratio of 0.82 (95% CI 0.55 to 1.22). ## Side effects reported In TRIUMPH-3, discontinuation because of adverse events was 9.8% on 9 mg and 13.5% on 12 mg, against 4.8% on placebo. The most frequently reported adverse events were diarrhoea in 30.1% on 9 mg and 24.4% on 12 mg against 8.7% on placebo, nausea in 21.7% on 9 mg and 22.4% on 12 mg against 5.8% on placebo, constipation in 18.0% on 9 mg and 15.7% on 12 mg against 7.1% on placebo and decreased appetite in 13.5% on 9 mg and 14.5% on 12 mg against 3.0% on placebo. | Event | 9 mg | 12 mg | Placebo | | --- | --- | --- | --- | | Discontinuation for adverse events | 9.8% | 13.5% | 4.8% | | Diarrhoea | 30.1% | 24.4% | 8.7% | | Nausea | 21.7% | 22.4% | 5.8% | | Constipation | 18.0% | 15.7% | 7.1% | | Decreased appetite | 13.5% | 14.5% | 3.0% | | Dysesthesia | 6.4% | 6.4% | 1.3% | | Urinary tract infection | 6.1% | 7.0% | 5.3% | Design ## Trial design and sources Compound Retatrutide Phase 3 Population Adults with severe obesity (BMI of 35 or more) and established cardiovascular disease, with or without type 2 diabetes Participants randomised 1,949 Duration 80 weeks Primary endpoint Percent change in body weight from baseline at 80 weeks Estimand efficacy Read out 23 July 2026 - Eli Lilly topline release, 23 July 2026 [open](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional) · checked 23 September 2026 - ClinicalTrials.gov NCT05882045 [open](https://clinicaltrials.gov/study/NCT05882045) · checked 23 September 2026 - Registry: NCT05882045 Questions ## TRIUMPH-3, answered ### What did TRIUMPH-3 find? In TRIUMPH-3, a phase 3 trial of retatrutide in adults with severe obesity (BMI of 35 or more) and established cardiovascular disease, with or without type 2 diabetes (n=1,949), mean body weight fell 21.6% on 9 mg and 22.6% on 12 mg over 80 weeks, against 3.2% on placebo (efficacy estimand; Eli Lilly topline release, 23 July 2026). ### What side effects were reported in TRIUMPH-3? In TRIUMPH-3, discontinuation because of adverse events was 9.8% on 9 mg and 13.5% on 12 mg, against 4.8% on placebo. The most frequently reported adverse events were diarrhoea in 30.1% on 9 mg and 24.4% on 12 mg against 8.7% on placebo, nausea in 21.7% on 9 mg and 22.4% on 12 mg against 5.8% on placebo, constipation in 18.0% on 9 mg and 15.7% on 12 mg against 7.1% on placebo and decreased appetite in 13.5% on 9 mg and 14.5% on 12 mg against 3.0% on placebo. Related ## More on retatrutide - [TRIUMPH-1](https://www.primaralabs.com/research/trials/triumph-1) - [TRIUMPH-2](https://www.primaralabs.com/research/trials/triumph-2) - [TRIUMPH-4](https://www.primaralabs.com/research/trials/triumph-4) - [Retatrutide phase 2 (Jastreboff)](https://www.primaralabs.com/research/trials/retatrutide-phase-2) - [TRIUMPH-5](https://www.primaralabs.com/research/trials/triumph-5) - [TRIUMPH-6](https://www.primaralabs.com/research/trials/triumph-6) - [TRIUMPH-7](https://www.primaralabs.com/research/trials/triumph-7) - [TRIUMPH-8](https://www.primaralabs.com/research/trials/triumph-8) - [TRIUMPH-9](https://www.primaralabs.com/research/trials/triumph-9) - [TRIUMPH-OUTCOMES](https://www.primaralabs.com/research/trials/triumph-outcomes) - [Evidence Map: Retatrutide](https://www.primaralabs.com/research/evidence#retatrutide) - [Retatrutide 20mg](https://www.primaralabs.com/marketplace/retatrutide) ## More videos Retatrutide vs Tirzepatide vs Semaglutide: Trials Compared (PH)1:55·[Transcript and chapters](https://www.primaralabs.com/videos/reta-vs-tirz-vs-sema)